Senti Biosciences Holdings, Inc. — Form SCHEDULE 13D/A
Filed July 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Celadon Partners SPV 24 filed an amended Schedule 13D/A on July 16, 2026, regarding beneficial ownership in Senti Biosciences Holdings, Inc. The filing document itself contains no substantive disclosures of specific ownership percentages, share counts, dollar amounts, or changes to previously reported positions — only header information and entity identifiers (CIK 0002060465 for filer; CIK 0001854270 for Senti Bio). The nature and magnitude of the amendment cannot be determined from the text provided.
Why this rating
Schedule 13D/A amendments are routine disclosure updates. Without visibility into actual ownership changes, share counts, or dollar amounts, significance cannot be elevated. Immaterial by default unless substantive amendment details were withheld from filing excerpt.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.